Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue reduced its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 52.5% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,030 shares of the biopharmaceutical company’s stock after selling 2,245 shares during the period. State of Alaska Department of Revenue’s holdings in Alnylam Pharmaceuticals were worth $558,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Vanguard Group Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company’s stock worth $1,792,542,000 after acquiring an additional 50,366 shares in the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company’s stock valued at $550,837,000 after buying an additional 201,784 shares in the last quarter. Capital International Investors grew its stake in Alnylam Pharmaceuticals by 1.8% in the 1st quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company’s stock valued at $545,674,000 after acquiring an additional 64,560 shares during the last quarter. Capital Research Global Investors increased its holdings in Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company’s stock valued at $470,018,000 after acquiring an additional 214,908 shares in the last quarter. Finally, Bellevue Group AG lifted its holdings in shares of Alnylam Pharmaceuticals by 3.7% in the first quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company’s stock valued at $137,238,000 after purchasing an additional 32,966 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ALNY. Morgan Stanley raised their price objective on shares of Alnylam Pharmaceuticals from $250.00 to $255.00 and gave the stock an “equal weight” rating in a research note on Friday, July 12th. Chardan Capital reissued a “buy” rating and set a $300.00 price target on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Barclays upped their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Scotiabank boosted their target price on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reissued a “neutral” rating and set a $220.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, October 11th. Six investment analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $294.50.

Alnylam Pharmaceuticals Trading Down 0.3 %

Shares of NASDAQ ALNY opened at $272.22 on Friday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a 1-year low of $141.98 and a 1-year high of $304.39. The business has a 50-day moving average of $273.88 and a 200-day moving average of $229.34.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The business had revenue of $500.90 million during the quarter, compared to analysts’ expectations of $532.91 million. During the same period in the previous year, the company posted $1.15 EPS. The firm’s revenue for the quarter was down 33.3% compared to the same quarter last year. As a group, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.67 EPS for the current year.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $280.00, for a total value of $4,200,000.00. Following the completion of the transaction, the chief executive officer now directly owns 73,441 shares of the company’s stock, valued at $20,563,480. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.